A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative ...

In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

Nearly 200 million Americans have high blood pressure, but new research suggests about 1-in-6 adults in the United States with hypertension don’t even know they have it. Dr. Natalie Azar joins TODAY ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

The pulmonary arterial hypertension treatment market has witnessed a significant transformation in recent years, driven by advancements in medical research and increasing awareness about rare ...

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

The FDA approved treprostinil (Yutrepia) inhalation powder for pulmonary arterial hypertension and pulmonary hypertension ...

Pulmonary arterial hypertension (PAH) is an incurable disease initiated by endothelial dysfunction, secondary to vascular inflammation and occlusive pulmonary arterial vascular remodeling, resulting ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...